--- title: "Kiora Pharmaceuticals (KPRX) news: offering" url: "https://aibio.space/companies/kiora-pharmaceuticals/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "KPRX offering news: Kiora reports second quarter 2026 results and cash runway into late 2028. Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), United States." --- KPRX Kiora Pharmaceuticals, Inc. NASDAQ · United States # Kiora Pharmaceuticals (KPRX) news KPRX offering news Company Updates · 2026-10-29 ## [Kiora in-licenses late-stage KIO-401 for retinal artery occlusion](https://aibio.space/news/kiora-licenses-late-stage-kio-401-retinal-artery-occlusion/) Kiora will pay $3.5 million upfront for exclusive rights outside Asia to KIO-401 from Senju Pharmaceutical. The company plans a multinational Phase 3 trial in CRAO, targeted to start in 2027. ## Latest Kiora Pharmaceuticals news 1. 2026-09-08 Company Updates [Kiora appoints Keith Lane as executive vice president of clinical development](https://aibio.space/news/kiora-appoints-keith-lane-executive-vice-president-clinical/) Kiora named Keith J. Lane, previously Chief Scientific Officer at Ora, Inc., to lead clinical development and regulatory affairs. The appointment supports the KIO-301 retinitis pigmentosa program. 2. 2026-08-19 Company Updates [Kiora licenses KIO-301 rights in South Korea to Chong Kun Dang](https://aibio.space/news/kiora-licenses-kio-301-rights-south-korea-chong-kun-dang/) Kiora will receive a $1 million upfront payment from Chong Kun Dang for KIO-301 rights in South Korea. Kiora says its partners will coordinate a single global Phase 3 trial in retinitis pigmentosa. 3. 2026-08-07 Company Updates [Kiora reports second quarter 2026 results and cash runway into late 2028](https://aibio.space/news/kiora-reports-second-quarter-2026-results-cash-runway-late-2028/) Kiora ended the quarter with about $16.8 million in cash and short-term investments. The company also reported a private placement for up to $24.0 million, with $5.0 million received upfront. 4. 2026-06-18 Company Updates [Kiora reports preclinical epilepsy data for ion channel modulator KIO-300](https://aibio.space/news/kiora-reports-preclinical-epilepsy-data-ion-channel-modulator-kio-300/) KIO-300 significantly suppressed seizure-associated activity in an ex vivo mouse temporal lobe epilepsy model, Kiora said. The poster was presented at the Epilepsy Foundation Pipeline Conference on June 18-19, 2026. 5. 2026-05-08 Company Updates [Kiora reports first quarter 2026 results and runway into late 2028](https://aibio.space/news/kiora-reports-first-quarter-2026-results-runway-late-2028/) Kiora ended the first quarter with $13.9 million in cash and short-term investments. It raised an additional $5.0 million in gross proceeds from a strategic equity investment after quarter end. 6. 2026-04-07 Financings [Kiora Pharmaceuticals closes private placement of up to $24 million](https://aibio.space/news/kiora-pharmaceuticals-closes-private-placement-up-24-million/) Kiora Pharmaceuticals, Inc. closed the deal with Perceptive Advisors and ADAR1 Capital Management on April 6, 2026, with $5.0 million in upfront funding. Up to $19 million more could come if milestone-based warrants are exercised. 7. 2026-04-02 Company Updates [Kiora's chief development officer Eric Daniels to depart April 17, 2026](https://aibio.space/news/kioras-chief-development-officer-eric-daniels-depart-april-17-2026/) Kiora said Eric J. Daniels, M.D., MBA, will leave his role as Chief Development Officer on April 17, 2026, and that the company has started a search for a successor. The company's ABACUS-2 and KLARITY trials continue. ## Kiora Pharmaceuticals at a glance - **Ticker**: KPRX - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $16.8 million ### Related companies - [Aclaris Therapeutics](https://aibio.space/companies/aclaris-therapeutics/) NASDAQ: ACRS - [Tarsus Pharmaceuticals](https://aibio.space/companies/tarsus-pharmaceuticals/) NASDAQ: TARS - [Jupiter Neurosciences](https://aibio.space/companies/jupiter-neurosciences/) NASDAQ: JUNS - [Parabilis Medicines](https://aibio.space/companies/parabilis-medicines/) NASDAQ: PBLS - [ACADIA Pharmaceuticals](https://aibio.space/companies/acadia-pharmaceuticals/) NASDAQ: ACAD - [Rhythm Pharmaceuticals](https://aibio.space/companies/rhythm-pharmaceuticals/) NASDAQ: RYTM - [Matinas Biopharma Holdings](https://aibio.space/companies/matinas-biopharma/) AMEX: MTNB - [Lisata Therapeutics](https://aibio.space/companies/lisata-therapeutics/) NASDAQ: LSTA ### Also on NASDAQ - [BioAge Labs](https://aibio.space/companies/bioage-labs/) BIOA - [Bone Biologics](https://aibio.space/companies/bone-biologics/) BBLG - [Zenas BioPharma](https://aibio.space/companies/zenas-biopharma/) ZBIO - [Oncolytics Biotech](https://aibio.space/companies/oncolytics-biotech/) ONCY - [Cytosorbents](https://aibio.space/companies/cytosorbents/) CTSO - [AURORA CANNABIS INC](https://aibio.space/companies/aurora-cannabis/) ACB ## Kiora Pharmaceuticals annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$0](https://www.sec.gov/Archives/edgar/data/1372514/000137251426000024/) | [$16.0 million](https://www.sec.gov/Archives/edgar/data/1372514/000137251426000024/) | | Research and development | [$10.8 million](https://www.sec.gov/Archives/edgar/data/1372514/000137251426000024/) | [$7.8 million](https://www.sec.gov/Archives/edgar/data/1372514/000137251426000024/) | | Net income (loss) | [-$10.8 million](https://www.sec.gov/Archives/edgar/data/1372514/000137251426000024/) | [$3.6 million](https://www.sec.gov/Archives/edgar/data/1372514/000137251426000024/) | | Cash from operations | [-$10.0 million](https://www.sec.gov/Archives/edgar/data/1372514/000137251426000024/) | [$8.6 million](https://www.sec.gov/Archives/edgar/data/1372514/000137251426000024/) | | Cash and equivalents | [$8.7 million](https://www.sec.gov/Archives/edgar/data/1372514/000137251426000074/) | [$3.8 million](https://www.sec.gov/Archives/edgar/data/1372514/000137251426000024/) | | Short-term investments | [$8.4 million](https://www.sec.gov/Archives/edgar/data/1372514/000137251426000074/) | [$23.0 million](https://www.sec.gov/Archives/edgar/data/1372514/000137251426000024/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $7.1 million, plus short-term investments of $9.8 million, $16.8 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Kiora Pharmaceuticals Has Kiora Pharmaceuticals raised money recently? Our latest story on this, dated Aug 7, 2026: "Kiora reports second quarter 2026 results and cash runway into late 2028". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/kiora-reports-second-quarter-2026-results-cash-runway-late-2028/). What is the ticker symbol of Kiora Pharmaceuticals? Kiora Pharmaceuticals, Inc. trades under the ticker KPRX on NASDAQ. Where is Kiora Pharmaceuticals listed? Kiora Pharmaceuticals, Inc. is listed on NASDAQ. What is the SEC CIK of Kiora Pharmaceuticals? The SEC Central Index Key (CIK) for Kiora Pharmaceuticals, Inc. is 1372514. Its filings are on SEC EDGAR. How many shares does Kiora Pharmaceuticals have outstanding? 4,424,387 shares as of 2026-08-05, per the cover page of its 10-Q filed 2026-08-07. Which country or territory is Kiora Pharmaceuticals listed under? Our directory records Kiora Pharmaceuticals, Inc. under United States. What does Kiora Pharmaceuticals do? Our directory classifies Kiora Pharmaceuticals, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Kiora Pharmaceuticals? The ISIN recorded for Kiora Pharmaceuticals, Inc. is US49721T5074. Does aibio.space cover Kiora Pharmaceuticals? aibio.space lists Kiora Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Kiora Pharmaceuticals incorporated? SEC records list its state or country of incorporation as DE. What was Kiora Pharmaceuticals's revenue last year? $0 for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Kiora Pharmaceuticals profitable? Kiora Pharmaceuticals, Inc. reported a net loss of $10.8 million for the fiscal year ended Dec 31, 2025, and used $10.0 million of cash in operations, per its annual report to the SEC. How much does Kiora Pharmaceuticals spend on research and development? $10.8 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Kiora Pharmaceuticals have? $16.8 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. What is the latest Kiora Pharmaceuticals (KPRX) stock news? Our latest story on Kiora Pharmaceuticals, dated Oct 29, 2026: "Kiora in-licenses late-stage KIO-401 for retinal artery occlusion". Kiora will pay $3.5 million upfront for exclusive rights outside Asia to KIO-401 from Senju Pharmaceutical. The company plans a multinational Phase 3 trial in CRAO, targeted to start in 2027. [Source](https://aibio.space/news/kiora-licenses-late-stage-kio-401-retinal-artery-occlusion/). ## Investor discussion: Kiora Pharmaceuticals Members talk about Kiora Pharmaceuticals (KPRX). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Kiora Pharmaceuticals, newest first. Each line links the filing it comes from. 1. 2026-04-07 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1372514/000137251426000036/ex991-pressreleasepipeapri.htm) ## Press releases Headlines of Kiora Pharmaceuticals's own announcements, newest first. Each opens the full release on the newswire that carried it. 1. 2026-10-29 Newsfile [Kiora Pharmaceuticals In-Licenses Late-Stage, Oral Neuroprotective Calpain Inhibitor for Central Retinal Artery Occlusion (CRAO) with Planned Expansion into NAION; Asset Completed Phase 3 Clinical Trial in CRAO in Japan](https://www.newsfilecorp.com/release/321503/Kiora-Pharmaceuticals-InLicenses-LateStage-Oral-Neuroprotective-Calpain-Inhibitor-for-Central-Retinal-Artery-Occlusion-CRAO-with-Planned-Expansion-into-NAION-Asset-Completed-Phase-3-Clinical-Trial-in-CRAO-in-Japan) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:KPRX on TradingView](https://www.tradingview.com/symbols/NASDAQ-KPRX/). ## SEC filings and registration - **SEC name**: Kiora Pharmaceuticals Inc - **CIK**: 1372514 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: KPRX (Nasdaq), KPHMW (OTC) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 169 SAXONY RD., ENCINITAS, CA, 92024 - **Phone**: 858-224-9600 - **Shares outstanding**: 4,424,387 as of 2026-08-05 (10-Q filed 2026-08-07) - **Former names**: EYEGATE PHARMACEUTICALS INC ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1372514/000137251426000079/kprx-20260908.htm) filed 2026-09-08 - [8-K](https://www.sec.gov/Archives/edgar/data/1372514/000137251426000077/kprx-20260819.htm) filed 2026-08-19 - [8-K](https://www.sec.gov/Archives/edgar/data/1372514/000137251426000075/kprx-20260807.htm) filed 2026-08-07 - [10-Q](https://www.sec.gov/Archives/edgar/data/1372514/000137251426000074/kprx-20260630.htm) filed 2026-08-07 - [8-K](https://www.sec.gov/Archives/edgar/data/1372514/000137251426000063/kprx-20260618.htm) filed 2026-06-18 - [8-K](https://www.sec.gov/Archives/edgar/data/1372514/000137251426000059/kprx-20260610.htm) filed 2026-06-11 - [S-3](https://www.sec.gov/Archives/edgar/data/1372514/000137251426000050/s-3xapril2026.htm) filed 2026-05-18 - [8-K](https://www.sec.gov/Archives/edgar/data/1372514/000137251426000048/kprx-20260508.htm) filed 2026-05-08 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001372514), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Kiora Pharmaceuticals, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker KPRX, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Kiora Pharmaceuticals, Inc. - **Ticker**: KPRX - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US49721T5074 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-KPRX/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/kiora-pharmaceuticals/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Kiora Pharmaceuticals (KPRX) news: offering", 2026-10-31, https://aibio.space/companies/kiora-pharmaceuticals/